[ad_1]
Swedish Vaccine Coordinator Richard Bergström doesn’t think it is on his table to think about a possible vaccine effectiveness when negotiating with vaccine manufacturers.
– No, it’s not my job that I like it. My job as a vaccine coordinator and negotiator for the EU is that we have access to as many as possible to choose from, says Richard Bergström.
Instead, it is the regulatory authorities, such as the Swedish Medical Products Agency together with the European Medicines Agency EMA, that will decide what an effective vaccine is, a topic that raises some discussion in research circles.
Many people think that the goals they The pharmaceutical companies that have reached an agreement with the European Medicines Agency are too low. One of the critics is Ali Harandi, director of the Sahlgrenska Academy’s vaccine laboratory in Gothenburg.
– The targets that have been set do not take into account serious illnesses, length of hospital stay or mortality rates, which are the decisive things when it comes to Covid, says Ali Harandi.
Helena Back, a clinical researcher with the infections group at the Uppsala Medical Products Agency, responds in this way to the criticisms of why the studies do not pretend to see if fewer people die from COVID-19 after being vaccinated.
– If you had that as your goal, you would have studies of the order of three to four million people, and that’s not really reasonable, he says.
Instead, the main objectives are who have fewer symptoms and Covid-19 diagnosed in the laboratory.
